Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corcept Therapeutics Inc. (CORT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-powered summaries that help explain their contents. Corcept is a Nasdaq-listed, commercial-stage pharmaceutical company focused on cortisol modulation in endocrinologic, oncologic, metabolic and neurologic disorders, and its filings offer detailed insight into this business.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Corcept describes its commercial activities with Korlym, which it identifies as the first FDA-approved medication for patients with endogenous hypercortisolism, as well as its research and development programs in hypercortisolism, solid tumors, ALS and liver disease. These periodic reports typically discuss product revenue, research and development spending, and risks related to drug development and regulation.
Current reports on Form 8-K, some of which are summarized in the data provided, disclose material events such as quarterly financial results, submission and FDA acceptance of New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application to the European Medicines Agency, and the receipt of an FDA Complete Response Letter for relacorilant in hypertension secondary to hypercortisolism. Other 8-K filings describe corporate developments, including changes to distribution agreements for Korlym and board-level changes accompanied by consulting arrangements.
On this page, users can review Corcept’s Forms 10-K, 10-Q and 8-K as they are made available from EDGAR, while AI-generated highlights point out key topics such as clinical trial updates, regulatory milestones, revenue trends and significant contracts. The filings section also surfaces exhibits referenced in 8-Ks, helping investors and researchers understand how Corcept’s cortisol-modulation strategy, pipeline progress and commercial operations are reflected in its official regulatory reporting.
BELANOFF JOSEPH K reported acquisition or exercise transactions in this Form 4 filing.
Corcept Therapeutics reported that Chief Executive Officer Joseph K. Belanoff received a grant of stock options covering 460,000 shares on February 27, 2026. These options give him the right to buy company stock and are structured as long-term incentive compensation.
The options vest in equal installments on each monthly anniversary of February 27, 2026, over a four-year period, and each vesting installment is conditioned on his continued service through the applicable vesting date.
Corcept Therapeutics' Chief Financial Officer receives a new stock option grant. On February 27, 2026, CFO Atabak Mokari was granted stock options covering 140,000 shares of Corcept Therapeutics common stock at an exercise price of $0.00 per share, recorded as a direct ownership position.
The options vest in equal monthly installments over four years, starting from the monthly anniversary of February 27, 2026, and require the executive’s continued service through each vesting date. After this grant, the reported derivative holdings from this award total 140,000 options.
Corcept Therapeutics reported that officer Sean Maduck received a grant of stock options covering 140,000 shares of the company’s stock. The award was recorded as an acquisition of derivative securities at no cash cost on the grant date.
According to the terms, these options vest in equal installments on each monthly anniversary of February 27, 2026 over a four-year period, and vesting requires Mr. Maduck’s continued service through each vesting date. Following this grant, he is shown as holding stock options for 140,000 shares directly.
Corcept Therapeutics reported that Chief Scientific Officer Hazel Hunt received a grant of stock options. The award covers 140,000 stock options with a stated exercise price of $0.00 per share, reflecting a compensatory equity grant rather than an open-market purchase.
These options begin vesting from February 27, 2026 and will vest in equal installments on each monthly anniversary of that date over a four-year period. Vesting is conditioned on Hunt’s continued service through each vesting date, tying the award to long-term employment and performance.
Robb Gary Charles reported acquisition or exercise transactions in this Form 4 filing.
Corcept Therapeutics granted Chief Business Officer Gary Charles Robb stock options covering 140,000 shares on February 27, 2026. These options vest in equal monthly installments over four years starting on February 27, 2026, subject to his continued service through each vesting date.
Corcept Therapeutics reported that Chief Development Officer William Guyer received a grant of stock options to acquire 140,000 shares of the company’s stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory award rather than an open-market purchase.
The options begin vesting on February 27, 2026 and will vest in equal monthly installments over a four-year period, contingent on Guyer’s continued service through each vesting date. Following this award, he holds stock options covering 140,000 shares directly.
Corcept Therapeutics director James N. Wilson reported several equity moves involving stock options and trust-related holdings. He exercised stock options for 100,000 shares of common stock at an exercise price of $3.88 per share through a derivative conversion.
Of the resulting shares, 10,636 shares of common stock were disposed of to cover the exercise price or tax liability at a price of $36.48 per share in a tax-withholding transaction. He then made a bona fide gift of 89,364 shares of common stock, transferring them without consideration to the James N. Wilson and Pamela D. Wilson Trust.
The filing shows 1,134,532 shares of common stock held indirectly by the James N. Wilson and Pamela D. Wilson Trust, 901,067 shares held indirectly by James and Pamela Wilson Family Partners, and 200,000 shares each held indirectly by the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust. Wilson has voting power over the trust and partnership shares pursuant to voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics is a commercial-stage biopharma focused on diseases driven by the stress hormone cortisol, including hypercortisolism, several solid tumors, liver disease and ALS. It already markets Korlym and an authorized generic in the United States for Cushing’s syndrome–related hypercortisolism.
The company’s lead selective cortisol modulator, relacorilant, received an FDA Complete Response Letter for hypercortisolism despite positive GRACE and GRADIENT data, and Corcept is working with the agency on a new approval path. Relacorilant plus nab-paclitaxel showed meaningful progression-free and overall survival benefits in platinum‑resistant ovarian cancer, supporting U.S. and EU marketing applications with a PDUFA date of July 11, 2026. Corcept is also advancing selective modulators miricorilant for MASH, dazucorilant for ALS (with Fast Track and orphan status, and a planned Phase 3 in 2026), and nenocorilant in combination with immunotherapy, funded by increasing R&D spending across a broad pipeline.
Corcept Therapeutics reported solid 2025 growth while earnings declined as it increased spending on development and commercialization. Revenue rose to $761.4 million from $675.0 million, and fourth-quarter revenue grew to $202.1 million from $181.9 million.
Full-year net income fell to $99.7 million from $141.2 million as selling, general and administrative expenses climbed to $448.7 million. The company ended 2025 with $532.4 million in cash and investments and spent $245.9 million on share repurchases and equity-related payments. It issued 2026 revenue guidance of $900–$1,000 million and highlighted an extensive pipeline, including NDAs for relacorilant in Cushing’s syndrome and platinum-resistant ovarian cancer, Phase 2b MASH data expected by the end of 2026, and plans for a Phase 3 ALS trial of dazucorilant.
Corcept Therapeutics reported that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym® does not infringe two Corcept patents covering methods of safely co‑administering Korlym with CYP3A4‑inhibiting drugs commonly used by patients with Cushing’s syndrome.
The decision affirms a prior December 2023 verdict from the Federal District Court for the District of New Jersey. Corcept’s CEO said the company is disappointed with the ruling and plans to vigorously defend its intellectual property, including evaluating options to seek further judicial review of the decision.